Clinical trials: Breakthrough Invasive Mold Infections
Invasive Mold Infections, Breakthrough Invasive Mold Infections
Breakthrough Invasive Mold Infections Under Posaconazole Prophylaxis (BIMI)
Invasive mold infections (IMI) mainly affect patients with hematologic malignancies receiving intensive chemotherapy or after hematopoietic stem cell transplantation (HSCT).
- Conditions
- Invasive Mold Infections, Breakthrough Invasive Mold Infections, Hematologic Malignancy, Hematologic Diseases
- Trial name
- BIMI (NCT04720144)
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois